iSpecimen Inc.
NASDAQ Capital MarketTotal Valuation
iSpecimen Inc. carries a market capitalization of 426,306.00, placing it among publicly traded companies globally. Its enterprise value stands at -2.55M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 426,306.00 |
| Enterprise Value | -2.55M |
Share Statistics
iSpecimen Inc. currently has 741,556.00 shares outstanding.
| Shares Outstanding | 741,556.00 |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 0.01, and the price-to-book ratio stands at 0.00.
| PE Ratio | N/A |
| PS Ratio | 0.01 |
| PB Ratio | 0.00 |
| P/TBV Ratio | -0.01 |
| P/FCF Ratio | 0.00 |
| P/OCF Ratio | 0.00 |
Enterprise Valuation
| EV / Sales | 1.86 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
iSpecimen Inc. maintains a current ratio of 0.62, meaning it holds 0.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 31.32, indicating elevated leverage, while an interest coverage ratio of -3,556.78 demonstrates limited ability to service its debt obligations.
| Current Ratio | 0.62 |
| Quick Ratio | 0.53 |
| Debt / Equity | 31.32 |
| Debt / EBITDA | -0.03 |
| Interest Coverage | -3,556.78 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -165.08 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
iSpecimen Inc.'s stock has declined approximately -93.95669% over the past 52 weeks. The 50-day moving average sits at 4.95, while the 200-day moving average is 20.11.
| Beta (5Y) | N/A |
| 52-Week Price Change | -93.95669% |
| 50-Day Moving Average | 4.95 |
| 200-Day Moving Average | 20.11 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, iSpecimen Inc. generated 1.03M in revenue and converted that into -11.10M in net income, yielding earnings per share of -153.56. EBITDA reached -8.44M, while operating income came in at -9.88M.
| Revenue | 1.03M |
| Gross Profit | -304,522.00 |
| Operating Income | -9.88M |
| Pretax Income | -11.10M |
| Net Income | -11.10M |
| EBITDA | -8.44M |
| EBIT | -9.88M |
| Earnings Per Share (EPS) | -153.56 |
Balance Sheet
iSpecimen Inc. holds 2.82M in cash and equivalents against 254,989.00 in total debt, resulting in a net debt position of -2.82M. Total book value stands at -84.62M, with working capital of -2.12M providing operational flexibility.
| Cash & Cash Equivalents | 2.82M |
| Total Debt | 254,989.00 |
| Net Debt | -2.82M |
| Equity (Book Value) | -84.62M |
| Book Value Per Share | -1,170.20 |
| Working Capital | -2.12M |
Cash Flow
iSpecimen Inc. produced -6.51M in operating cash flow over the past twelve months. After subtracting -454.00 in capital expenditures, free cash flow totaled -6.51M - equivalent to -89.98 per share.
| Operating Cash Flow | -6.51M |
| Capital Expenditures | -454.00 |
| Free Cash Flow | -6.51M |
| FCF Per Share | -89.98 |
Margins
iSpecimen Inc. operates with a gross margin of -29.64, reflecting its pricing power and cost economics. The operating margin of -961.36 and net profit margin of -1,080.72 provide insight into operational efficiency.
| Gross Margin | -29.64 |
| Operating Margin | -961.36 |
| Pretax Margin | -1,080.72 |
| Profit Margin | -1,080.72 |
| EBITDA Margin | -821.78 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -90,223.96 |
| FCF Yield | -57,305.77 |
Stock Splits
iSpecimen Inc.'s most recent stock split took place on April 28, 2026 with a 40:1 split ratio.
| Last Split Date | 4/28/2026 |
| Split Ratio | 40:1 |
Scores
iSpecimen Inc. posts an Altman Z-Score of -40.44, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -40.44 |